Background: Immune therapies have revolutionized cancer treatment over the last few years by allowing improvements in overall survival. However, the majority of patients is still primary or secondary resistant to such therapies, and enhancing sensitivity to immune therapies is therefore crucial to improve patient outcome. Several recent lines of evidence suggest that epigenetic modifiers have intrinsic immunomodulatory properties, which could be of therapeutic interest.
Introduction
Immune therapies have revolutionized oncology over the last few years by improving patient survival in several aggressive tumours. This has led to numerous practice-changing drug approvals in multiple malignancies including melanoma, thoracic and urothelial cancers, as well as Hodgkin lymphoma and mismatch repairdeficient tumours [1] [2] [3] [4] [5] . However, with the exception of these latter two diseases, the vast majority of patients still do not respond to immune therapies, highlighting the need for developing rational combinatorial approaches.
Several factors have been shown to influence the likelihood of response to immune therapies, including mutational burden and neoantigen load [6] , neoantigens clonality and quality [7, 8] , expression of antigen presenting molecules and immune checkpoints [9] , interferon-gamma (IFNc) responsiveness [10] , and composition of the tumour microenvironment ('hot' versus 'cold' tumours) [11] [12] [13] [14] . Although combinations of immune therapies have been proposed to address resistance, they have often led to a significant increase in severe immune-related toxicities [15] . The possibility of combining immune and non-immune therapies to achieve the desired immunomodulatory effect appears therefore as an interesting alternative option to sensitize immune-resistant tumours to immune therapies.
Epigenetics describes changes in gene expression that are not attributable to a change in the DNA sequence. Each cellular 2 m of DNA is tightly packed into a 10 lM nucleus in the form of chromatin where it is associated to histone proteins. There are three main levels of epigenetic regulation within chromatin: DNA methylation, histone post-translational modifications and chromatin remodelling. These epigenetic modifications regulate multiple dynamic cellular processes, including transcription, cell lineage and differentiation [16, 17] . Several recent lines of evidence support that epigenetic modulation of cancer or immune cells could modify their immunological properties and sensitize tumours to immune therapies. Drugs targeting the epigenome therefore appear as having a promising immunomodulatory potential that could be clinically exploited.
Here, we review the immunomodulatory properties of the most recent epigenetic drugs and discuss how these molecules could be rationally combined with immune therapies to enhance the antitumour immune response.
Epigenetic drugs
The basic unit of chromatin is the nucleosome, constituted of 146 bp DNA wrapped around a histone octamer. Two linker histones are deposited in the 20-80 bp DNA between nucleosomes and help stabilizing this region and organizing chromatin. Histones can undergo post-translational modifications, including methylation, acetylation, ubiquitination, phosphorylation, SUMOylation, ADP-ribosylation and citrullation. This constitutes the so-called 'histone code' that has functional consequences on signalling (including transcription, heterochromatin formation and DNA damage repair) [18] . The DNA methylation also regulates gene expression, with hypermethylation at promotors classically resulting in gene transcription silencing. Aberrant DNA methylation and mutations in enzymes regulating this process (e.g. DNMT, TET and IDH) have been associated with cancer [19] [20] [21] .
Several hundreds of proteins involved in DNA or histone modifications represent targets for epigenetic therapies [22, 23] . Schematically, we can distinguish four main types of epigenetic enzymes: (i) the 'writers', which put the marks on histones or DNA; (ii) the 'readers', that recognize these marks; (iii) the 'erasers', which remove it; and (iv) the 'remodelers', which mobilize or exchange histones [24] (Figure 1 ). Of note, many epigenetic enzymes have several functional domains which confer them multiple of the above described functions.
The first epigenetic modifiers developed were DNA methyl transferase inhibitors (DNMTis) and histone deacetylase inhibitors (HDACis), which are approved in some hematologic malignancies. DNMTis are cytidine analogues that, when incorporated into the DNA, block the action of DNMT and cause their degradation. The resulting loss of DNA methylation favours the re-expression of aberrantly silenced proteins, including tumour suppressor genes, cancer-associated antigens and components of the antigen presentation machinery (reviewed in [25] ). HDACis inhibit the removal of acetyl group from lysines on histones, and have pleiotropic antitumor effects including growth arrest, apoptosis or differentiation [26] .
Several new classes of small molecules have recently been developed to specifically target epigenetic regulators, such as Bromodomain and Extra-Terminal motif (BET), Enhancer of Zeste Homolog 2 (EZH2), Lysin-Specific Demethylase 1 (LSD1), Disruptor of Telomeric silencing 1-like (DOT1-L) and Protein Arginine N-Methyltransferase 5 (PRMT5) inhibitors. BET family proteins recognize acetylated lysines on histone tails, and facilitate the recruitment of transcriptional proteins to promote transcription activation and elongation [27] . More than 10 BETi are currently in early development; activity has been clinically observed in NUT midline carcinoma [28] , as well as pre-clinically in MYC-and transcription factors-driven diseases [29] [30] [31] . EZH2i block the histone methyltransferase activity of the catalytic subunit of the chromatin remodelling Polycomb Repressive Complex 2 (PRC2) [32] . Impressive clinical activity of EZH2i has been observed in follicular lymphoma and diffuse large B-cell lymphoma harbouring EZH2 activating mutations [33] , as well as in some selected SWI/SNF-deficient solid tumours [34] . LSD1i promote H3K4 methylation, allowing the expression of genes involved in cell differentiation which are aberrantly silenced in some cancers [35] ; several LSD1 inhibitors are currently evaluated in early phase clinical trials.
Epigenetic immunomodulation of the tumour cell Immunogenic cell death
Immunogenic cell death (ICD) is a specific form of death which allows tumour cells to enter the cancer-immunity cycle. This multi-step process, which traditionally involves endoplasmic reticulum stress, autophagy, apoptosis and secondary necrosis, allows modifications in the composition of the cell surface and release of soluble mediators in the microenvironment [36] . These latter enhance the recruitment of dendritic cells (DCs) and favours tumour antigen presentation to T cells. Two pan-HDACi, panobinostat and vorinostat, have been reported to induce ICD in mouse models of colon adenocarcinoma and leukemia/lymphoma [37] . This is in line with previous observations suggesting that the antitumor effect of vorinostat was abolished in mice lacking immune effectors (including Gzmb-encoding Granzyme B-or Rag2 and Il2rg [38] ), but was increased in combination with immune-stimulating antibodies [39] . The potential for BET inhibitors to induce ICD has also been suggested, both in monotherapy in mesothelioma models and in combination with ATR inhibitors in melanoma models [40] (Figure 2 ).
Cell-autonomous immunomodulatory effects of epigenetic modifiers
DMNT and HDAC inhibitors. DNMTis and HDACis have the ability to boost the antitumor immune response, by favouring the expression of components of the antigen presentation machinery, by increasing the presentation of cancer testis antigens or neoantigens and by enhancing the IFN response [41] [42] [43] [44] [45] .
Excellent recent reviews have been published by expert groups on this topic [25, 46] , and the main immunomodulatory effects of these drugs are summarized in Figure 2 .
EZH2 inhibitors. EZH2 inhibition can directly influence immunogenicity of cancer cells either by acting on the antigen presentation process or by rewiring the microenvironment. MHC-II regulation plays an important role in the triggering and control of adaptive immune response, by allowing antigen presentation to CD4þ T cells. Constitutive and inducible MHC-II expression is tightly regulated by CIITA, its master regulator. CIITA belongs to the IFNc-stimulated genes (ISGs) group, and is rapidly induced at promotor pIV [47] [48] .
Two more recent studies highlighted the potential for EZH2i and DNA methyltransferase 1 (DNMT1) inhibitors to rewire a 'cold' to a 'hot' microenvironment. In the first study, Peng et al., using a mouse model of ovarian cancer, reported increased expression of the Th1-type chemokines CXCL9 and CXCL10 upon EZH2i and DNMT1i exposure, resulting in increased T-cell trafficking in the tumour microenvironment which enhanced therapeutic efficacy of programmed death-ligand 1 (PD-L1) checkpoint blockade as well as adoptive T-cell therapy [49] . EZH2 and DNMT1 expression in human ovarian tumour samples were negatively correlated with outcome and CD8þ T-cell infiltrates. These findings were further extended to colon cancer cell lines and tissue samples in a second study, where expression of SUZ12 and EED (two other components of PRC2) had the same prognostic value and immune infiltration pattern as EZH2 [50] .
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Immunogenic cell death Antigen presentation machinery Figure 1 . Epigenetic drugs mechanism of action and levels of immunomodulatory effects. Coloured shapes on histone tails represent random histone modifications (e.g. acetylation, methylation, SUMOylation, etc.). One chromatin remodelling complex is depicted. 5hmC, 5-hydroxymethyl cytosine; 5mC, 5-methyl cytosine.
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BET inhibitors. BET inhibitors (BETi) have initially been described as having anti-inflammatory properties [51, 52] , because BRD4-their main target-is a key regulator of transcription initiation and elongation of pro-inflammatory genes. As such, one might hypothesize that they would have a detrimental effect on the anticancer immune response. However, more and more recent data are piling up that support that BETi have intrinsic immunomodulatory properties that favour antitumour immunity. Zhu et al. first described in 2016 that CD274, the gene encoding PD-L1, was a direct target of BRD4: BETi directly suppressed PD-L1 transcription in cancer and immune cells [53] .
Using an ovarian cancer mouse model, authors showed that BETi could limit tumour progression and improve mice survival by increasing the IFNc-and Granzyme B-producing CD8þ T cells infiltrates. Hogg et al. further reported that IRF1 was coregulating this BRD4-mediated IFNc-induced transcriptional regulation of PD-L1, which was independent from Myc expression [54] . In this study, the adjunction of the BETi JQ1 to immune-stimulating therapies (anti-PD-1 or anti-CD137 antibodies) allowed to improve survival of El-Myc lymphoma bearing mice. Another very recent study analysed changes in mRNA expression in the blood of patients with metastatic castration resistant prostate cancer treated with ZEN-3694. This BETi induced a significant down-regulation of several checkpoints receptors (including PD-L1, TIM3 and A2AR) as well as cytokines/ chemokines (IL-8, CXCR1 and CCR2), while co-stimulatory factors remained unchanged [55] . Interestingly, low drug exposures to BETi showed higher activation of T-cell signalling pathways than high exposures. Although data are still very scarce, BETi might also influence innate immunity, as BRD2 is located within the MHC-II complex on chromosome 6 [56] [57] [58] . Finally, BETi could favour the activation of cGAS-STINGmediated type 1 IFN response, through the induction of Hexamethylene bis-acetamide-inducible protein 1 (HEXIM 1). This RNA-binding protein is a robust pharmacodynamic biomarker of BETi activity [59] , and a role for HEXIM 1 in building a ribonuclear complex (HDP-RNP) that regulates the activation of innate immune response to foreign DNA through the cGAS-STING pathway has recently been reported [60] .
LSD1 inhibitors.
A repressive role for LSD1 in pro-inflammatory cytokine expression (including IL1a, IL1b, IL6 and IL8) has initially been described, in monotherapy and combination with HDAC1 inhibitors [61] , suggesting that LSD1i might favour the restauration of antitumour immunity. Interestingly, Konovalov et al. recently examined LSD1 mRNA levels in series of ovarian cancer samples and evidenced that LSD1 mRNA overexpression correlated with down-regulation of genes involved in the immune/inflammatory response and poorer outcome [62] .
Epigenetic regulation of the immune system
Maturation and activation of immune cells are thoroughly regulated at the epigenetic level. From the start of their lineage commitment, immune cells are characterized by distinct trends of DNA methylation according to the myeloid or lymphoid lineage [63] . Once the immune cell reaches its 'specialized functional status', further maturation is often regulated by metabolic characteristics of the microenvironment, where many metabolites [e.g. alpha ketoglutarate (aKG), acetyl-CoA, or lactate] act as cofactors of epigenetic modifiers [64] . The cancer microenvironment is generally characterized by a profound metabolic dysregulation, resulting in altered epigenetic status of the immune cells which usually favours immunosuppression [65, 66] . Epigenetic modulation might therefore represent a novel original strategy to reverse immunosuppression.
T cells
CD8þ T cells. The generation of memory T cells directed against cancer-specific neoantigens is a key factor in achieving longlasting responses on immune therapy. Memory T cells are typically multipotent T cells that maintain long-term plasticity and survival. Conversely, effector T cells have a limited survival, are very dependent on antigen presence and become easily exhausted upon chronic antigen exposure. Lineage and commitment of effector or memory T cells are tightly regulated by histone modifications-silencing of pro-memory genes following H3K27me3 or H3K9me3 deposition by EZH2 [67] [68] [69] or Suv39h1, respectively (Pace, Science 2018 doi 10.1126/science.aah6499)-or DNA methylation [70, 71] . Exhausted T cells are characterized by persistent expression of several checkpoint inhibitors such as PD-1, TIM3 and exhaustion markers, which correlate with a specific epigenetic profile [72] [73] [74] ; this epigenetic rigidity prevents re-invigoration and might limit immune checkpoint blockers (ICBs) efficacy [72] . Interestingly, pre-treatment with DNMTi rejuvenated tumour infiltrating CD8þ T cells and reversed resistance in ICB-resistant models [75] . BETi have also been reported to enhance the effects of adoptive immunotherapy in a mouse leukemia model, by favouring the maintenance of CD8þ T cells with functional properties of stem cell-like and central memory T cells [76] . Genome organizers, such as SATB1, have further been involved in the prevention of premature T-cell exhaustion by regulating Pdcd1 expression [77] . Also, loss of chromatin accessibility around the IL7R locus and genes of its associated JAK/STAT signalling cascade has been linked to aging and impaired T-cell response [78] . CD4þ T cells are pro-tumorigenic. This T-cell plasticity is notably regulated by the expression of specific PRC2-regulated transcription factors (e.g. Tbet, GATA3 and Eomes) and epigenetic marks at promoters of specific lineage genes which orientate towards Th1 or Th2 differentiation (e.g. H3K9me3 vs H3K9ac) [16] ; defects in EZH2 have been reported to favour Th1 orientation in preclinical settings [79] . Further, lineage commitment to memory CD4þ T cells also seems regulated at the epigenetic level [80] . If clinical implications of this epigenetic imprinting have mostly been studied in autoimmune diseases [81] , it deserves further assessment in oncology.
Regulatory T cells. Regulatory T cells (Treg) are characterized by the expression of the FOXP3 transcription factor, which plays an essential role in immune suppression [82, 83] . Chromatin modifiers, such as SATB1, are crucial for initial steps of Treg development [84] . FOXP3 expression is further regulated by EZH2-dependent chromatin modification [85] and DNA methylation [86] . Interestingly, CDK4/6 inhibitors such as abemaciclib have recently been reported to suppress Treg proliferation by causing p21 overexpression following reduced DNMT1 levels and CDKN1a promotor hypomethylation [87] . BETi also have the potential to decrease Treg-mediated immunosuppression and synergize with HDAC6 inhibitors to promote antitumour T-cell response in non-small-cell lung cancer (NSCLC) mouse models and human tumour samples [88] .
Macrophages
Macrophages are specialized immune cells that have opposite functions towards tumour cells in murine models: M1 macrophages display antitumour phagocytotic properties, whereas M2 macrophages are pro-tumorigenic. Although such classification is less consensual in human immunology, these dual roles have also been described in tumours [89] , notably in ICB-resistant tumour samples [90] . The microenvironment characteristics (notably cytokine and metabolic profiles) influence macrophage epigenetics and activation status [64, [91] [92] [93] . For example, chronic TNF and IL-1 signalling-traditionally considered as favouring the antitumour immune response-can become deleterious through the induction of pro-tumorigenic macrophages [94] ; the metabolite alpha-ketoglutarate promotes M2 activation via the JMJD3 histone demethylase activation [66] , and other metabolites (including acetyl-coA, succinate and citrate) are key co-factors of several chromatin-remodelling enzymes that govern macrophage fate (reviewed in [64] ) (Figure 3 ). Hypoxia is a typical characteristic of the tumour microenvironment, which favours the pro-tumorigenic status of tumour-associated macrophages (TAMs) that can secrete pro-angiogenic agents. Guerriero et al. recently reported that TMP195, an HDACIIa inhibitor, increased TAMs infiltration and induced intra-tumour vasculature normalization in a murine model of breast carcinoma, leading to antitumour effects [95] . Interestingly, vascular normalisation favours adequate cytotoxic CD8þ T-cell tumour infiltration [96, 97] .
BRD4 deletion in macrophages has been reported to cause increased activation of eIF4E, and subsequently reduced NF-jBdependent innate immune response [98] . The DNA methylcytosine dioxygenase TET2 has also been reported to be highly expressed in TAMs of patients with malignant melanoma, and its sustained expression favours the immunosuppressive epigenetic program [99] . Adeegbe et al. further recently showed that the HDAC6 inhibitor ricolinostat could promote the activation of antigen-presenting cells (including TAMs), in peripheral blood of NSCLC patients as well as in a mouse NSCLC model [88] (Figure 3) . Finally, studies carried out in a glioma mouse model suggest that the microglia orientation is dependent H4K16 acetylation [100] . Such examples support that epigenetic strategies might allow modulating macrophages' status and thereby antitumour immunity.
Myeloid-derived suppressor cells and DCs
Antigen presentation is important function of several myeloid cells including myeloid-derived suppressor cells (MDSCs) and DCs, whose antitumour potential largely depends on their ability to activate T cells. Epigenetic modifiers, such as HDACi and DNMTi, have been shown to directly increase both MHC-II and costimulatory molecules (CD40 and CD86) expression in peripheral MDSCs of breast and lung cancer patients [88, 101, 102] . DC maturation is also governed by chromatin regulators, such as SATB1 that regulates MHC-II expression and modulates their anti-tumorigenic potential [103] .
NK cells
NK cells have direct tumour cell-killing properties, which are regulated by various inhibitory receptors such as KIR and NKG2A. NK cells are typically activated and more cytotoxic in presence of IFNc, which induces trained immunity [104] . These characteristics can be enhanced by EZH2 inhibition [105, 106] , as well as BET inhibition that induces NK activating ligands and receptors [55] . comprehensive review of interplay between epigenetics, immune response and metabolic signalling goes beyond the scope of this manuscript, epigenetic regulation of some key metabolic immunomodulators, such as the tryptophan-catabolic enzyme Indoleamine-2,3-dioxygenase 1 (IDO1), has been described [55, 107] .
Immuno-metabolism and tumour microenvironment

Challenges of the clinical development of epigenetic drugs as immunomodulators General considerations
Evidence summarised above supports the potential of epigenetic modifiers to enhance tumour immunogenicity and several clinical trials are currently evaluating this approach (Table 1) . Although available data are still scarce, results from the NSCLC cohort of the first trial combining an epigenetic modulator-the HDACi entinostat-and an ICB-the anti-PD-1 pembrolizumab-were reported at SITC [102] . Response rates were 24% (14/17 patients) and 10% (3/31 patients) in the anti-PD(L)1-naïve and anti-PD(L)1-resistant patient groups, respectively. Of note, responses in this latter group were observed in PD-L1-low or -null tumours by IHC. Interestingly, very recent data evidenced that some major chromatin remodelling complexes (including the PBAF form of SWI/SNF) influenced cytotoxic T-cell infiltration and resistance to ICB [108, 109] . Several challenges will need to be considered to optimally develop epigenetic-immune therapy combinations. (i) The optimal drug sequence still needs to be determined. An initial observation of partial response in three (60%) five patients with NSCLC pre-exposed to low-dose epigenetic modifiers and subsequently treated with nivolumab (versus 15% response rate in the overall trial population), and disease control achieved in all five patients at 24 weeks, rose high interest [25, 41] . This sequential strategy, consisting of an 'epigenetic priming' phase-where the epigenetic agent is administered in monotherapy to achieve the desired immunomodulation-followed by a combination phase, is currently being evaluated in dedicated trials notably in microsatellite-stable colorectal cancer and NSCLC. Beyond the preclinical rationale, such design offers the opportunity to compare in each individual patient the clinical and biological effect of the epigenetic drug in monotherapy first, and then of the combination. (ii) The optimal dose of epigenetic drug that should be administered can be debated. The use of the highest tolerable dose might not be necessary to obtain the desired epigenetic modulation, and lower but continuous dosing might allow achieving the targeted immunomodulatory effect while limiting drug-related detrimental adverse events or 'collateral' effects that result from these drugs' pleiotropism [51, [110] [111] [112] [113] [114] [115] . The use of dedicated pharmacodynamics companion biomarkers and regular immunomonitoring may guide optimal dosage determination. (iii) Comprehensive translational studies should be carried out to determine whether the observed effect is linked to the effect of the epigenetic drug on the tumour or immune cell, or both. Such biomarkers should include epigenetic marks (e.g. loss of H3K27me3 or modulation of HEXIM1 on EZH2 and BET inhibitor treatment, respectively), markers of cell death (apoptosis or ICD), neoantigens characterization (quantity and clonality), immune checkpoint expression, transcriptional networks activation, description of immune infiltrates (nature and quantity), evaluation of immune cells differentiation and activation status, TCR repertoire characterisation, as well as cytokine, chemokine and inflammation markers dosage [11, 14, 116] . These markers should be evaluated primarily in tumour samples but also in circulating material (circulating tumour and immune cells, circulating tumour DNA for mutational load and methylation changes, plasma for cytokine dosage and fresh blood for immunophenotyping). For example, a promising signature called 'MeTIL', which is uniquely based on profiling DNA methylation markers of TILs, showed better ability to predict outcome (survival and response) on chemotherapy in breast cancer, lung cancer and melanoma, than conventional histopathological assessment [117] . (iv) Considering the potential for both epigenetic drugs and immune therapies to cause paradoxical effects, early tumour evaluation should be recommended to identify patients presenting hyperprogressive disease (HPD) [118] [119] [120] [121] . It is of critical importance that such cases, which should not be under-reported, undergo exhaustive exploration to not only identify predictive biomarkers of HPD, but also investigate whether the epigenetic agent (e.g. by influencing T-cell exhaustion or immune memory) or the immune therapy, might have favoured HPD. Conversely, when the epigenetic modulation aims at enabling cell differentiation, protocol provisions may be considered to allow patients with stable (or slowly progressive) disease to remain on trial, as chronic drug exposure is often required to achieve differentiation [122, 123] . (v) The histotype-specificity of the effects should be studied, for example through the development of basket studies involving multiple histologies. Indeed, contrary to immune therapies that can be efficient in several tumour types sharing the same molecular characteristics in a histology-agnostic fashion [1, 124] , the effect of epigenetic drugs is often histotype-specific and transcriptional programme-dependent.
(vi) Dedicated cohorts should allow to clearly distinguish immuno-naïve, immune-refractory and immune-resistant patients, as biological rationales underlying an epigenetic-immune therapy combination are significantly different in each of these populations. (vii) Improvements in overall survival should not by default be solely attributed to immune therapies. Epigenetic therapies have indeed shown to be involved in the eradication of 'persister' cells that are responsible for resistance to treatment [115, 125] . Whether such 'persisters' also drive resistance to immune therapies has not been described yet, but could be investigated in such trials. (viii) The causality of adverse events presented in epigenetic-immune therapies combination trials should be thoroughly evaluated. Although there is minimal overlapping toxicity between these agents, some adverse events-such as cytopenias or bone marrow hypocellularity-could be attributed to both agents, but therapeutic management would significantly differ according to the physiopathology. Finally, specific provisions should be made to favour the participation of paediatric patients. Although long-term side effects of epigenetic therapies can be feared in such populations, drug-induced epigenetic modifications are usually reversible, and doses that are administered to adults have classically been shown to be equally safe in younger patients [126, 127] . 
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Innovative trial designs
Because epigenetic modulators may affect the immune response via a wide range of pleiotropic effects, it is important to evaluate them beyond the classical criteria such as tumour shrinkage and duration of response. We believe that correlative immune and molecular readouts are of essential value when testing epigenetic modulators alone or in combination with other IO compounds. One clear path to achieve this is the use of such compounds in neoadjuvant trials (also called window of opportunity trials) [128, 129] . This concept is particularly suitable to be tested in resectable breast cancer or head and neck squamous cell carcinoma. In that setting, all tumour-or immune-related biomarkers could be evaluated in large surgical samples and compared with baseline tumour material ( Figure 4 ).
Discussion Conclusion
Contrary to genetic alterations, epigenetic plasticity allows rapid, dynamic and flexible changes that favour immune escape, resistance to therapies and feed all hallmarks of cancer [130] . Therefore, targeting epigenetic alterations represents a promising therapeutic approach and epigenetic therapies could have a major clinical impact, notably in combination with conventional therapies and immune therapies [131, 132] . The overall satisfactory tolerance of epigenetic drugs, their large therapeutic range, their intrinsic immunomodulatory effects and the minimal overlapping toxicities make them attractive partners to combine with immune therapies. Results of ongoing clinical trials and preclinical studies will allow a deeper understanding of The research was conducted between 11 April 2017 and 5 November 2017 on clinicaltrial.gov;
'not yet recruiting', 'recruiting', 'enrolling by invitation' and 'active, not recruiting' studies that contained the following terms were selected: checkpoint targets (PD-1, PD-L1, PD-L2, CTLA-4, KIR, CD137, GITR, TIM3, TIGIT, LAG3, OX40), immunomodulatory drugs (aldesleukin, imiquimod, interferon, mifamurtide, sipuleucel-T, tasonermine), other immunotherapies (CAR-T cell, anticancer vaccines, BCG), epigenetic targets and drugs (EZH2, HDAC, BET, LSD1, PRMT5, azacitidine, decitabine, guadecitabine). Clinical trials combining at least one epigenetic drug and at least one anticancer immunotherapy were considered. When trials are constituted of several arms, each arm is depicted on a different row. (1) 'Yes': epigenetic priming phase is clearly defined in the schedule of the trial. 'No': no epigenetic priming or schedule not described in clinicaltrial.gov. (2) The trial is described as 'epigenetic priming' but consists of a combination phase followed by immunotherapy alone. (3) Parallel assignment between multiple arms; the estimated enrolment reflects the total number of patients included in the trial. (4) 'Yes': previous treatment with immunotherapy is allowed, even if a 'wash-out' period is required.
the interplay between tumour immune escape and epigenetic plasticity, and hopefully lead to significant progresses in fighting cancer.
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Resected surgical sample
Large tumour blocks The drug of interest is administered to a treatment-naïve patient before the curative surgery and for a short period of time. This allows studying specifically treatment-induced changes in tumour and microenvironment on large resected tumour samples without delaying curative surgery.
